The vaccine goal

Accelerate the uptake and use of new and underused vaccines

The first 10 years of GAVI's work focused mainly on catalysing adoption of vaccines against yellow fever, hepatitis B (hepB) and Haemophilus influenzae type b (Hib).

In the next decade, GAVI will maintain momentum on these antigens but also target new vaccines, which hold the greatest potential to achieve progress on the Millennium Development Goals (MDG), in particular MDG 4 - the reduction of child mortality.

100 new vaccine introductions

GAVI's ambition is to accelerate the introduction of routine meningitis, pneumococcal and rotavirus vaccines and support campaigns against yellow fever and meningitis.

Goal-level indicators

Number of GAVI supported countries introducing underused and new vaccines.
Coverage of underused and new vaccines in GAVI supported countries.
View GAVI's targets for its vaccine goal

Strategic objectives

Increase evidence-based decision-making by countries.
Strengthen country introduction to help meet demand.
View detailed business objectives for GAVI's vaccine goal

The Alliance will also begin activities to prepare for other new vaccines, including human papillomavirus (HPV), Japanese encephalitis, typhoid and rubella.

If the Alliance is fully resourced to meet demand, up to 100 new vaccine introductions across GAVI-eligible countries would occur during the second five-year strategy. The majority of these introductions are pneumococcal and rotavirus vaccines.

Rwanda's pneumococcal vaccine roll-out, one year on

12 months after Rwanda became the first African country to introduce pneumococcal vaccine, UNICEF visit Nyamata health centre to check on progress in the fight against the continent’s number one child killer.